← All trials
NCT06809322
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2025
- Primary completion
- Apr 13, 2035
- Completion date
- May 31, 2037
- First posted
- Feb 5, 2025
- Last posted
- May 1, 2025
- Enrollment
- 468
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- Canadian Cancer Trials GroupCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.